Update on the management of familial central nervous system tumor syndromes

Current Neurology and Neuroscience Reports

Volumn 7, Issue 3, 2007, Pages 200-207

  Hottinger, Andreas F ^b   Khakoo, Yasmin ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; LOMUSTINE; RAPAMYCIN; SORAFENIB; SUNITINIB; TIPIFARNIB; TUMOR SUPPRESSOR PROTEIN; VIGABATRIN; VINCRISTINE;

ALLELE; AUTOSOMAL DOMINANT INHERITANCE; BASAL CELL NEVUS SYNDROME; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COWDEN SYNDROME; DIAGNOSTIC PROCEDURE; FAMILIAL CANCER; GENE IDENTIFICATION; HOMEOSTASIS; HUMAN; MOLECULAR GENETICS; NEUROFIBROMATOSIS; OPTIC NERVE GLIOMA; PATHOPHYSIOLOGY; REVIEW; SOMATIC MUTATION; TUBEROUS SCLEROSIS; TURCOT SYNDROME; VON HIPPEL LINDAU DISEASE;

BASAL CELL NEVUS SYNDROME; CENTRAL NERVOUS SYSTEM NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HAMARTOMA SYNDROME, MULTIPLE; HIPPEL-LINDAU DISEASE; HUMANS; LI-FRAUMENI SYNDROME; NEOPLASTIC SYNDROMES, HEREDITARY; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; TUBEROUS SCLEROSIS;

EID: 34249678301     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-007-0031-5     Document Type: Review

References (71)

1. Gutmann DH: The neurofibromatoses: when less is more. Hum Mol Genet 2001, 10:747-755.
2. Friedman JM: Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999, 89:1-6.
3. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988, 45:575-578.
4. Quigg M, Rust RS, Miller JQ: Clinical findings of the phakomatoses: neurofibromatosis. Neurology 2006, 66:E23-24.
5. Hofman KJ, Harris EL, Bryan RN, Denckla MB: Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 1994, 124:S1-8.
6. Rosser TL, Vezina G, Packer RJ: Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 2005, 64:553-555.
7. Rawal A, Yin Q, Roebuck M, et al.: Atypical and malignant peripheral nerve-sheath tumors of the brachial plexus: report of three cases and review of the literature. Microsurgery 2006, 26:80-86.
8. Bausch B, Borozdin W, Neumann HP: Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med 2006, 354:2729-2731.
9. Jahraus CD, Tarbell NJ: Optic pathway gliomas. Pediatr Blood Cancer 2006, 46:586-596.
10. Ogura T, Adachi J, Nishikawa R, et al.: Synchronous optic and pineal pilocytic astrocytomas in a paediatric patient with neurofibromatosis type 1. Pediatr Neurosurg 2004, 40:301-305.
11. Deliganis AV, Geyer JR, Berger MS: Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma. Neurosurgery 1996, 38:1114-1148; discussion 1118-1119.
12. King A, Listernick R, Charrow J, et al.: Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet 2003, 122:95-99.
13. Opocher E, Kremer LC, Da Dalt L, et al.: Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer 2006, 42:1807-1816.
14. Listernick R, Louis DN, Packer RJ, Gutmann DH: Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NFl Optic Pathway Glioma Task Force. Ann Neurol 1997, 41:143-149.
15. Listernick R, Ferner RE, Piersall L, et al.: Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology 2004, 63:1944-1946.
16. Astrup J: Natural history and clinical management of optic pathway glioma. Br J Neurosurg 2003, 17:327-335.
17. Walker D: Recent advances in optic nerve glioma with a focus on the young patient. Curr Opin Neurol 2003, 16:657-664.
18. Widemann BC, Salzer WL, Arceci RJ, et al.: Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006, 24:507-516.
19. Perilongo G, Moras P, Carollo C, et al.: Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: a real possibility. J Child Neurol 1999, 14:352-356.
20. Broniscer A, Gajjar A, Bhargava R, et al.: Brain stem involvement in children with neurofibromatosis type 1: role of magnetic resonance imaging and spectroscopy in the distinction from diffuse pontine glioma. Neurosurgery 1997, 40:331-337; discussion 337-338.
21. Packer RJ, Ater J, Allen J, et al.: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997, 86:747-754.
22. Grill J, Couanet D, Cappelli C, et al.: Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 1999, 45:393-396.
23. Hamaratoglu F, Willecke M, Kango-Singh M, et al.: The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2005, 27-36.
24. Hirokawa Y, Tikoo A, Huynh J, et al.: A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J 2004, 10:20-26.
25. Baser ME, Friedman JM, Aeschliman D, et al.: Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002, 71:715-723.
26. Evans DG, Huson SM, Donnai D, et al.: A clinical study of type 2 neurofibromatosis. Q J Med 1992, 84:603-618.
27. Parry DM, Eldridge R, Kaiser-Kupfer MI, et al.: Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994, 52:450-461.
28. Evans DG, Baser ME, O'Reilly B, et al.: Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 2005, 19:5-12.
29. Brennan JW, Rowed DW, Nedzelski JM, Chen JM: Cerebrospinal fluid leak after acoustic neuroma surgery: influence of tumor size and surgical approach on incidence and response to treatment. J Neurosurg 2001, 94:217-223.
30. Evans DG, Birch JM, Ramsden RT, et al.: Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006, 43:289-294.
31. Ho SY, Kveton JF: Rapid growth of acoustic neuromas after stereotactic radiotherapy in type 2 neurofibromatosis. Ear Nose Throat J 2002, 81:831-833.
32. Lenarz T, Lim HH, Reuter G, et al.: The auditory midbrain implant: a new auditory prosthesis for neural deafness - concept and device description. Otol Neurotol 2006, 27:838-843.
33. Mayfrank L, Mohadjer M, Wullich B.: Intracranial calcified deposits in neurofibromatosis type 2. A CT study of 11 cases. Neuroradiology 1990, 32:33-37.
34. Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. N Engl J Med 2006, 355:1345-1356.
35. Roach ES, Gomez MR, Northrup H: Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998, 13:624-628.
36. Thiele EA: Managing epilepsy in tuberous sclerosis complex. J Child Neurol 2004, 19:680-686.
37. Curatolo P, Bombardieri R, Verdecchia M, Seri S: Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment. J Child Neurol 2005, 20:318-325.
38. Goh S, Butler W, Thiele EA: Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 2004, 63:1457-1461.
39. Sutton LN: Current management of low-grade astrocytomas of childhood. Pediatr Neurosci 1987, 13:98-107.
40. Franz DN, Leonard J, Tudor C, et al.: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006, 59:490-498.
41. Bader RS, Chitayat D, Kelly E, et al.: Fetal rhabdomyoma: prenatal diagnosis, clinical outcome, and incidence of associated tuberous sclerosis complex. J Pediatr 2003, 143:620-624.
42. Seizinger BR, Rouleau GA, Ozelius LJ, et al.: Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988, 332:268-269.
43. Shuin T, Yamasaki I, Tamura K, et al.: Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol 2006, 36:337-343.
44. Linehan WM, Lerman MI, Zbar B: Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995, 273:564-570.
45. Glasker S: Central nervous system manifestations in VHL: genetics, pathology and clinical phenotypic features. Fam Cancer 2005, 4:37-42.
46. Richard S, Campello C, Taillandier L, et al.: Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group. J Intern Med 1998, 243:547-553.
47. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH: The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 2003, 98:82-94.
48. Dwarakanath S, Suri A, Sharma BS, Mehta VS: Intracranial hemangioblastomas: an institutional experience. Neurol India 2006, 54:276-278.
49. Conway JE, Chou D, Clatterbuck RE, et al.: Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease. Neurosurgery 2001, 48:55-62.
50. Weil RJ, Lonser RR, DeVroom HL, et al.: Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2003, 98:95-105.
51. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
52. Motzer RJ, Bukowski RM: Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006, 24:5601-5608.
53. Singh AD, Shields CL, Shields JA: von Hippel-Lindau disease. Surv Ophthalmol 2001, 46:117-142.
54. Manski TJ, Heffner DK, Glenn GM, et al.: Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 1997, 277:1461-1466.
55. Kleihues P, Schauble B, zur Hausen A, et al.: Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997, 150:1-13.
56. Olivier M, Goldgar DE, Sodha N, et al.: Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003, 63:6643-6650.
57. Frebourg T, Abel A, Bonaiti-Pellie C, et al.: Li-Fraumeni syndrome: update, new data and guidelines for clinical management. Bull Cancer 2001, 88:581-587.
58. Taylor MD, Mainprize TG, Rutka JT: Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery 2000, 47:888-901.
59. Gorlin RJ: Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987, 66:98-113.
60. Vortmeyer AO, Stavrou T, Selby D, et al.: Deletion analysis of the adenomatous polyposis coli and PTCH gene loci in patients with sporadic and nevoid basal cell carcinoma syndrome-associated medulloblastoma. Cancer 1999, 85:2662-2667.
61. Raffel C: Medulloblastoma: molecular genetics and animal models. Neoplasia 2004, 6:310-322.
62. Albright AL, Wisoff JH, Zeltzer PM, et al.: Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery 1996, 38:265-271.
63. Hubbard JL, Scheithauer BW, Kispert DB, et al.: Adult cerebellar medulloblastomas: the pathological, radiographic, and clinical disease spectrum. J Neurosurg 1989, 70:536-544.
64. Packer RJ, Sutton LN, Elterman R, et al.: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994, 81:690-698.
65. Louis DN, von Deimling A: Hereditary tumor syndromes of the nervous system: overview and rare syndromes. Brain Pathol 1995, 5:145-151.
66. Hamilton SR, Liu B, Parsons RE, et al.: The molecular basis of Turcot's syndrome. N Engl J Med 1995, 332:839-847.
67. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP: PTEN is essential for embryonic development and tumour suppression. Nat Genet 1998, 19:348-355.
68. Backman S, Stambolic V, Mak T: PTEN function in mammalian cell size regulation. Curr Opin Neurobiol 2002, 12:516-522.
69. Chow LM, Baker SJ: PTEN function in normal and neoplastic growth. Cancer Lett 2006, 241:184-196.
70. Lyons CJ, Wilson CB, Horton JC: Association between meningioma and Cowden's disease. Neurology 1993, 43:1436-1437.
71. Tuli S, Provias JP, Bernstein M: Lhermitte-Duclos disease: literature review and novel treatment strategy. Can J Neurol Sci 1997, 24:155-160.